The $50M ASR is a clear signal of management's view that the stock is undervalued and will mechanically reduce share count by ~4.8%, providing a modest EPS tailwind. Traders should watch for the final settlement details in Q4 2026 and any subsequent updates on the remaining $100M authorization.
COLL drugs
COLL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $28.15entry
- T+1 · 3mo ago +0.28%α +0.48% · $28.23
- T+5 · 3mo ago −2.17%α −0.20% · $27.54
- T+20 · 2mo ago −19.18%α −17.44% · $22.75
- T+60 · 11d ago −14.00%α −8.52% · $24.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of a previously authorized $150 million buyback program. The company will receive an initial delivery of ~1.56 million shares (80% of expected total) based on the $25.70 closing price, with final settlement by Q4 2026. This signals management's confidence in the company's valuation and capital allocation, though it does not provide new information on underlying business fundamentals.
Key Facts
- Collegium entered an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock.
- The ASR is part of a $150 million share repurchase program authorized by the Board in July 2025.
- Initial delivery of 1,556,420 shares based on the $25.70 closing price on August 12, 2026, representing ~80% of expected total repurchase.
- Final settlement expected no later than Q4 2026; as of June 30, 2026, Collegium had ~32.5 million shares outstanding.
Financial Impact
$50 million accelerated share repurchase, representing ~4.8% of shares outstanding at the initial delivery price (1.56M shares / 32.5M shares outstanding)
Risk Factors
- The buyback does not address underlying business fundamentals or revenue growth trajectory.
- If the stock price declines further, the ASR locks in repurchases at a higher average cost than if the company had waited.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-095464 |
| Document: 0001104659-26-095464-index-headers.html | 0001104659-26-095464 |
| Document: 0001104659-26-095464-index.html | 0001104659-26-095464 |
| Document: 0001104659-26-095464.txt | 0001104659-26-095464 |
Track record
24 reports on COLL
0 of 5 bullish or bearish reports moved the stock their way by T+1. Best: −1.39% at T+1 after the Nov 9, 2026 report. 0 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers